Some days are confusing, others are trend changers, Jim Cramer told his Mad Money viewers Thursday. With so many crosscurrents going on in the stock market right now, it's important to know which is which.
Investors need to remember that the market has been rallying on the promise of tax cuts, deregulation and repatriation, Cramer told viewers, which is why anything that runs contrary to that agenda will be viewed negatively.
Thus with Congress seemingly focused on repealing the Affordable Care Act, tax cuts appear on the back burner.
Then there is the economy, which appears to be slowing if the latest jobs data are to believed. That news sent interest rates lower, taking the bank stocks with them. The market cannot rally without the banks, Cramer said. Is this just an outlier? Only time will tell.
Cramer said the good news is that money is not leaving the stock market, it's simply moving from the new winners back to the old winners, stocks like Facebook (FB) and Apple (AAPL) , two Action Alerts PLUS holdings.
Executive Decision: Box
For his "Executive Decision" segment, Cramer again spoke with Aaron Levie, chairman and CEO of Box (BOX) , the cloud software provider, shares of which are up 5% over the past week.
Levie explained that Box simplifies how companies work and collaborate in an increasingly complex world. He said his company currently has more than 69,000 customers globally and is a part of 63% of the Fortune 500.
When asked about competition, Levie said that Box is the only platform that can scale to meet the needs of all enterprise use cases, but they also partner with many companies, including IBM (IBM) , Microsoft (MSFT) and Google.
Cramer said with so many positive things going in its favor, Box should be much bigger.
In the dog-eat-dog world of retail, a world where consumers increasingly prefer to shop online, is there still room for department stores? Cramer said sadly, no.
Cramer recounted when both of his parents once worked for venerable department stores that, at the time, everyone felt would last forever.
The mall is indeed dead, Cramer said. The rents are simply too high for many retailers and frankly, consumers just don't like shopping there anymore. What's most surprising, though, is the speed at which all of this is happening. Just two years ago, Macy's booked its best holiday season ever. This year, it's closing stores and laying off thousands of associates.
None of the retailers have a plan forward, Cramer concluded, which leaves them out in the open for Amazon's continued carpet bombing.
Executive Decision: Constellation Brands
In his second "Executive Decision" segment, Cramer also checked in with Rob Sands, president and CEO of Constellation Brands (STZ) , the wine and spirits maker that just posted a 24-cents-a-share earnings beat on inline revenues, but saw shares fall 7% on fears Donald Trump may impose an import tax on the company's products, notably Corona, which hails from Mexico.
Sands started off by saying that Constellation had a fantastic quarter and the company feels shares continue to be undervalued, which is why they've purchased more than $800 million worth of their own stock.
As for the volatility in Constellation shares, Sands said that investors are worried about tax changes. He said that while it's not possible to make a Mexican beer outside of Mexico, there are steps Constellation can take to mitigate any hit to their bottom line.
Sands concluded by saying that innovation continues at Constellation and there is "lots of great new stuff in our portfolio."
Cramer was bearish on U.S. Silica Holdings (SLCA) .
Executive Decision: Halozyme Therapeutics
For his third and final "Executive Decision" segment, Cramer welcomed Dr. Helen Torley, president and CEO of Halozyme Therapeutics (HALO) , a stock that shot up 18% today after the company released positive Phase II trial results for its pancreatic cancer treatment.
Torley said that pancreatic cancer is among the most devastating forms of cancer, but the Phase II data just released proved that they've been able to improve the time to progression of the disease and reduce the rate of blood clots among the 250 patients in the study.
Torley added that Phase II studies are done to confirm that a drug is on the right track and she said the data has been very supportive that the design and implementation is a good one. Phase III studies are now underway at 200 centers around the world.
Cramer cautioned that Halozyme is a speculative stock, but if investors are looking for speculation for their portfolio, this is one they should consider.
Cramer and Jack Mohr are transforming Action Alerts PLUS into an interactive club format to give members what they need more of: Cramer. Now. Get a free subscription.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.